ANIP ANI Pharmaceuticals, Inc.
Healthcare$81.41-1.58%ClosedMarket Cap: $1.85B
As of 2026-05-26
Valuation
P/E (TTM)
23.20
PEG
0.05
P/B
3.08
P/S
2.04
EV/EBITDA
8.01
DCF Value
$1,043.40
FCF Yield
8.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
65.9%
Operating Margin
13.4%
Net Margin
9.7%
ROE
17.3%
ROA
6.3%
ROIC
8.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $237.5M | 51.8% | $38.7M | $29.5M | $— | — |
| Q4 null | $247.1M | 96.2% | $48.2M | $27.5M | $— | — |
| FY null | $883.4M | 51.0% | $81.2M | $78.3M | $— | — |
| Q3 null | $227.8M | 49.1% | $22.8M | $24.1M | $— | — |
| Q2 null | $211.4M | 64.7% | $13.9M | $8.5M | $— | — |
| Q1 null | $197.1M | 62.9% | $26.2M | $15.7M | $— | — |
| Q4 null | $190.6M | 57.9% | $-4.4M | $-10.3M | $— | — |
| FY null | $614.4M | 59.3% | $584.0K | $-18.5M | $— | — |
| Q3 null | $148.3M | 57.5% | $-20.5M | $-24.2M | $— | — |
| Q2 null | $138.0M | 58.2% | $5.2M | $-2.3M | $— | — |
| Q1 null | $137.4M | 64.2% | $20.3M | $18.2M | $— | — |
| Q4 2023 | $131.7M | 59.4% | $6.7M | $1.2M | $0.04 | — |